Related Experiment Video

Updated: Dec 13, 2025

Flow Cytometric Analysis of Apoptotic Biomarkers in Actinomycin D-Treated SiHa Cervical Cancer Cells
13:53

Flow Cytometric Analysis of Apoptotic Biomarkers in Actinomycin D-Treated SiHa Cervical Cancer Cells

Published on: August 26, 2021

5.3K

Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment

Siti Fairus Abdul Rahman1, Benedict Shi Xiang Lian2, Nethia Mohana-Kumaran1

  • 1School of Biological Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia.

Future Oncology (London, England)
|July 28, 2020
PubMed

Insights

Targeting anti-apoptotic proteins BCL-XL and MCL-1 with BH3-mimetics shows promise for cervical cancer treatment. This approach leverages the specific dependencies of cancer cells on these survival proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The B-cell lymphoma 2 (BCL-2) family of proteins regulates apoptosis.
  • Anti-apoptotic proteins like BCL-XL and MCL-1 are critical for cancer cell survival.
  • BH3-mimetics are a class of drugs designed to target these anti-apoptotic proteins.

Purpose of the Study:

  • To review the expression levels of anti-apoptotic proteins in cervical cancer.
  • To explore the potential of targeting BCL-XL and MCL-1 with BH3-mimetics in cervical cancer.

Main Methods:

  • Literature review focusing on studies of BCL-2 family proteins in cervical cancer.
  • Analysis of techniques for determining cancer cell dependency on specific anti-apoptotic proteins.
  • Evaluation of preclinical data on BH3-mimetic efficacy.

Main Results:

  • BCL-XL and MCL-1 are identified as key survival proteins in cervical cancer cells.
  • Co-targeting BCL-XL and MCL-1 with BH3-mimetics demonstrates significant efficacy in cervical cancer cell lines.
  • Expression levels of these proteins can vary, influencing therapeutic strategies.

Conclusions:

  • Cervical cancer cells exhibit addiction to BCL-XL and MCL-1 for survival.
  • Selective BH3-mimetics targeting BCL-XL and MCL-1 represent a promising therapeutic strategy for cervical cancer.
  • Further research into expression patterns and targeted therapies is warranted.
Keywords:
BCL-2 selective inhibitorsBCL-XL selective inhibitorsBH3-mimeticsMCL-1 selective inhibitorscervical cancer

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.6K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K